{"disease":{"id":"nab-paclitaxel","name":"nab paclitaxel"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04138719","title":"Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":520,"lead_sponsor_name":"Hebei Medical University Fourth Hospital","has_results":false},{"nct_id":"NCT04159142","title":"Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":414,"lead_sponsor_name":"Hebei Medical University Fourth Hospital","has_results":false},{"nct_id":"NCT03779464","title":"Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":132,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT07126119","title":"Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Tianjin Medical University Second Hospital","has_results":false},{"nct_id":"NCT07233252","title":"Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Tianjin Medical University Second Hospital","has_results":false},{"nct_id":"NCT07125547","title":"Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Tianjin Medical University Second Hospital","has_results":false},{"nct_id":"NCT07089199","title":"Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer(TitAN) : A Prospective, Single-Arm, Phase II Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":34,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}